Fatemeh Fathi; Ahmad Hamta
Abstract
Breast cancer is the second most common cancer worldwide and the most prevalent cancer among women, causing a large number of deaths annually. This fact underscores the importance of studying the risk factors, diagnostic methods, and treatments for this disease. Single nucleotide polymorphisms are the ...
Read More
Breast cancer is the second most common cancer worldwide and the most prevalent cancer among women, causing a large number of deaths annually. This fact underscores the importance of studying the risk factors, diagnostic methods, and treatments for this disease. Single nucleotide polymorphisms are the most common type of genetic variation in eukaryotic genomes and are found in many genes associated with various cancers. Depending on their location within different regions of a gene, these genetic variants can differently affect gene expression and cancer susceptibility. In this case-control study, we investigated the single nucleotide polymorphisms of the GPR30/GPER-1 gene, including rs3808350, rs3808351, and rs11544331, and their association with breast cancer risk. The study was conducted on 70 breast cancer patients and 70 healthy women from the female population of Markazi Province, Iran. Blood samples were collected from all participants, and DNA was extracted. The target polymorphisms were genotyped using the tetra-primer amplification refractory mutation system PCR (tetra-ARMS PCR) method. Data analysis was performed using SPSS Statistics 26 and SNP Analyzer 2 software. The results showed a significant association between the AG genotype (co-dominant model) and the combined GG and AG genotypes (dominant model) of rs3808350 with increased breast cancer risk. For rs11544331, the TT genotype (recessive model) and the combined TT and CT genotypes (dominant model) were also significantly associated with higher risk. No significant association was observed for rs3808351. In conclusion, rs3808350 and rs11544331 polymorphisms may serve as potential biomarkers for early detection and risk assessment of breast cancer. Identifying such genetic markers could enhance diagnostic accuracy and support the development of personalized prevention and treatment strategies.
Masoumeh Aalipour; Asghar Aalipour; Mohammad Mousaei Ghasroldasht
Abstract
Colorectal cancer (CRC) and gastric cancer (GC) are multifactorial diseases likely influenced by genetic susceptibility. Gastric cancer is also the fourth most common cancer in the world and the second leading cause of cancer-related mortality. CD86 (B7-2) is a costimulatory molecule found on antigen-presenting ...
Read More
Colorectal cancer (CRC) and gastric cancer (GC) are multifactorial diseases likely influenced by genetic susceptibility. Gastric cancer is also the fourth most common cancer in the world and the second leading cause of cancer-related mortality. CD86 (B7-2) is a costimulatory molecule found on antigen-presenting cells (APCs) that is important in autoimmune, transplantation, and tumor immunity. This protein is expressed in the immune system cells and is involved in the pathogenesis of various inflammatory disorders and inflammation. Rs17281995 polymorphism is located in section 3’ UTR, and given the regulatory role of 3' UTR gene sequences, SNPs located in these regions can affect the expression and function of the corresponding protein. In the present study, the relationship between rs17281995 polymorphism located in the 3' UTR regulatory region of the CD86 gene sequence and the risk of colorectal and gastric cancer in Iranian patients was analyzed. Polymorphism was identified in 26 patients with colorectal cancer, 30 patients with gastric cancer, and 36 healthy controls using the high-resolution DNA melting curve analysis (HRM) technique. The Data was then analyzed using SPSS software. There was no significant relationship between rs17281995 polymorphism and colorectal (P = 0.75) and gastric cancers (P = 0.97) in the Iranian population. In addition, genotypic distribution analysis showed no significant difference between the patient and control groups (P˃0.05). Among people with colorectal cancer, 0.577 had the G allele and 0.423 had the C allele. In the control group, 0.639 had the G allele and 0.361 had the C allele. In conclusion, our data indicate that the CD86 rs17281995 gene polymorphism does not seem to be a risk factor for colorectal and gastric cancers in the Iranian population.
